Press release - June 16th, 2011
Promising results for a study into using transcutaneous Vagus nerve stimulation for hard to treat epilepsies
ERLANGEN, Germany, 16.06.2011 – The pilot study into treating therapy resistant epilepsies using NEMOS confirms the initial, positive, intermediate results from June 2010. NEMOS, from cerbomed GmbH, is the first device worldwide for transcutaneous Vagus Nerve Stimulation (t-VNS). The study produced positive indications for safety, tolerability and effectiveness, along with verifying the high user-friendliness of t-VNS.
The prospective pilot study was carried out over 9 months at the epilepsy center of the University Hospital Erlangen, under the supervision of Professor Dr. Hermann Stefan. Patients, who for many years had suffered from drug-resistant epilepsy, used t-VNS for more than three hours a day.
A decrease in the frequency and duration of hard to treat epileptic incidences was achieved for 5 of 7 patients using t-VNS.
The director of the clinical trial, Professor Dr. Stefan, explains: "Altogether, t-VNS can be judged as a safe and compatible method for long-term application. As such, it represents a possible therapy alternative for patients with hard to treat epilepsies."
"The result of the pilot study is another important milestone for our company. It motivates us to carry out a worldwide, multi-center study for t-VNS therapy from the middle of the year, and lays the foundation stone for a successful market launch," says Prof. Dr. Jens Ellrich, Chief Medical Officer at cerbomed.
t-VNS is an outpatient therapy and is carried out by the patient. The trancutaneous vagus nerve stimulator NEMOS consists of a stimulation unit and an ear electrode which the patient wears in the ear like an earphone. This electrode stimulates the auricular branch of the vagus nerve through the skin. Cerbomed expects t-VNS to offer a highly attractive and cost-effective alternative to current and emerging VNS treatments, other neurostimulation methods, surgery or pharmacologic therapies.
Cerbomed is a privately held, medical device company based in Erlangen, Germany, aiming to become the leader for the development of non-invasive vagus nerve stimulation (VNS) therapies. The company was founded in 2005 to develop and commercialize its proprietary, transcutaneous Vagus Nerve Stimulation (t-VNS) technology and devices for therapeutic uses. NEMOS products comprise the world’s first non-invasive VNS device enabling specific electrical brain stimulation. The company has received a CE-mark for NEMOS in Europe.